Brooks D. Cash, MD, FACG1, Mary Beth Moncrief, PhD2
1University of Texas Health Science Center, Houston, TX; 2Synchrony Medical Communications, West Chester, PA
Introduction: NER1006 is a 1L PEG bowel prep approved in the US in 2018 for colonoscopy in adults. An online survey assessed real-world ease of use and treatment satisfaction in US adults who received NER1006 as a bowel prep.
Methods: Patients were recruited from community GI practices throughout the US and provided with a kit number to enroll online. Within 2 weeks post-colonoscopy, an online survey was to be completed by each patient. Survey questions included evaluation of patient history of colonoscopy and prior bowel prep(s) prescribed, experience during administration of NER1006, and patient satisfaction with the bowel prep process. A 9-point predefined grading scale was used to evaluate ease of NER1006 preparation and consumption (range, 1 “very difficult” to 9 “very easy”); importance of volume requirement and importance of clear liquid choice (range, 1 “not important at all” to 9 “very important”); and patient satisfaction (range, 1 “not satisfied at all” to 9 “very satisfied”). Data were deidentified and summarized using descriptive statistics.
Results: 1630 patients were enrolled (707 health care providers); 1606 patients had a colonoscopy and 1598 completed the survey from Sept 2018 through Feb 2019. Of the 1606 patients, 62.5% were female and 34.9% were male (2.6% not reported); mean age was 54.4 y (range, 18-89 y). While data were unknown for 8 of the 1606 patients, most (74.7%) did not report a family history of colon cancer, this was not the first colonoscopy for 62.6%, and 64.8% were undergoing colonoscopy for routine screening. A majority of the 1598 patients (76.1%) reported that NER1006 was very easy to prepare and take/administer (Table), and 89.9% of patients were very or moderately satisfied with NER1006 overall (Figure). Most (97.6%) patients consumed all/most of the prep. Also, 84.7% of 1005 patients with previous bowel prep use stated that their experience with NER1006 was much better/better (65.3%) or about the same (19.4%) compared with bowel preps they had previously used (Table).
Discussion: In this first real-world, multicenter survey, patient experience with NER1006 as a bowel prep for colonoscopy was favorable and adherence was high. The majority of patients were very/moderately satisfied with the overall experience and found it much better/better than other bowel preps used.
Funding: Salix Pharmaceuticals. BD Cash participated in study, enrolled 3 patients, and reviewed content for scientific accuracy. Patients were compensated for their time for completing survey.
Citation: Brooks D. Cash, MD, FACG; Mary Beth Moncrief, PhD. P0372 - PATIENT EXPERIENCE WITH NER1006 AS A BOWEL PREPARATION FOR COLONOSCOPY: A PROSPECTIVE, MULTICENTER U.S. SURVEY. Program No. P0372. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.